differentiating sarcomatoid mesothelioma from pleomorphic carcinoma of the lung, and poorly differentiated chest wall sarcoma. Hence it frequently poses a diagnostic challenge for pulmonary pathologists. In this pilot study we evaluated the diagnostic performance of two recently proposed IHC biomarkers, GATA-3 and MUC4, in conjunction with BAP1. Method: Sarcomatoid mesothelioma or sarcomatoid-predominant biphasic mesothelioma (10 cases), pleomorphic carcinoma of the lung (10 cases) and poorly differentiated primary or metastatic chest wall or pleural sarcoma (10 cases) were retrieved from our diagnostic archive. Resections or large biopsies were selected over small biopsies whenever possible. All the cases were diagnosed between 2009 and 2017 by a specialist pulmonary pathologist and discussed at the local multi-disciplinary team meeting in relation to final diagnosis. Whole slide GATA-3 (L50-823, pre-diluted), MUC4 (8G7, 1:50) and BAP1 (C-4, 1:50) immunohistochemistry was performed using Ventana Benchmark ULTRA system. Lymphocytes (GATA-3/ BAP1) and bronchiolar epithelium (MUC4) were used as internal positive controls. Loss of GATA-3/BAP1 and MUC4 staining was defined as complete loss of nuclear or membrane and cytoplasmic signals, respectively. Any staining intensity above the external negative controls was accepted as positive. Extent of positive staining was grouped as <1%, 1-50% and >50%. Result: GATA-3 was positive in 8/10 sarcomatoid mesothelioma, 6/10 chest wall/pleural sarcoma and 2/10 pleomorphic carcinoma of the lung. MUC4 positivity was observed exclusively in pleomorphic carcinoma of the lung (6/10), but only focally. BAP1 loss was infrequently observed in all three types of tumours. Conclusion: The combination of GATA-3 and MUC4 immunohistochemistry show promise as markers that would help in distinguishing these three tumours. The role of BAP1 is uncertain. These pilot results warrant an extended study that consists of a larger cohort to evaluate the utility of these biomarkers.
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F. Zito Marino, 1 M. Accardo, 1 G. Poziello, 1 A. Ronchi, 1 V. Ciaramella, 2 G. Vicidomini, 3 M. Santini, 3 F. Morgillo, 2 R. Franco 1 1 Pathology Unit, University of Campania "luigi Vanvitelli", Naples, Italy, Naples/IT, 2 Department of Internal and Experimental Medicine "f. Magrassi E A. Lanzara", Institute of Medical Oncology, University of Campania "luigi Vanvitelli", Naples, Italy, Naples/IT, 3 Thoracic Surgery Unit, University of Campania "luigi Vanvitelli", Naples, Italy, Naples/IT Background: Malignant pleural mesothelioma (MPM) is a highly aggressive and rare tumour arising from the pleura, primarily associated with asbestos exposure. Therapeutic options are limited to surgical resection, chemotherapy and thoracic radiation, unfortunately no target therapies are currently recommended for MPM. Previous studies suggested that the activation of multiple receptor tyrosine kinases (RTKs) play a central role in MPM pathogenesis and progression. In this context, AXL, c-MET and VEGFR2 overexpression could represent new possible therapeutic targets in MPM. Method: A Tissue MicroArray of MPM was built, including 40 epithelioid 7 sarcomatoid and 11 mixed. AXL, c-MET and VEGFR2 expression was assessed by Immunohistochemistry using specific antibodies. Fluorescence in Situ Hybridization analysis were performed in order to define AXL and c-MET genes stauts, using LSI AXL 19q13.2/CEN19q probes and LSI MET 7q31.2/CEN7 probes, respectively. Studies in vitro were performed in a wide panel of human MPM cell lines according to different histological type of original tumor, including epithelioid type (NCI-H290, NCI-H2052, NCI-H2452), sarcomatoid type (NCI-H205, NCI-H2373, NCI-H28), and biphasic type (Y-MESO-8A, Y-MESO-14, MSTO-211H). Result: AXL expression was observed in 16.6% of cases, while altered gene status in 14.5% of cases, including cases harboring gene amplification and polisomy of chromosome 19. However, no association was observed between AXL immunhistochemical expression and gene amplification. MET protein expression was observed in 20.8% of cases, while gene amplification was identified only in 2.0% of cases. VEGFR2 overexpression was identified in 31.25% of cases. 10.4% of cases showed co-expression of AXL and MET proteins, related significantly with epithelioid histotype (p < 0.05) and 6.25% of cases AXL, c-MET and VEGFR2 co-expression. Studies in vitro showed that multitargets inhibitor blocked cancer cell proliferation, metastasis and angiogenesis in four human mesothelioma cell lines: NCI-H2452, NCI-H2052, NCI-H28 and MSTO. A dose dependent inhibition of cell viability was examined after 72h treatment of human mesothelioma cell lines with increasing doses of multitargets inhibitor, observing a decrease in cell proliferation with IC50 value between 0.5 and 1 mM. Similar effects were detected for apoptosis assay and anchorage-independent colony forming abilities, in particular migration ability of H2052 and MSTO cell lines decreased to about 60% with 0.5 and 1 mM of multitargets inhibitor. Conclusion: AXL/c-MET/VEGFR2 co-expression represents a frequent event in MPM, especially in epithelioid phenotype, suggesting a possible cooperation of these RTKs in the pathogenesis of this neoplasia. Multitargets AXL/c-MET/VEGFR2 inhibitors could be a promising therapeutic weapon in mesothelioma. Background: With the recent clinical success of immunotherapy in non-small cell lung carcinoma, the character of the inflammatory infiltrate associated with these tumors is now the subject of increasing interest. Molecular studies have suggested that tumors can be stratified by the character of their inflammatory infiltrate. We now describe the detailed histological appearances of a multi-institutional series of early stage squamous carcinomas and correlate them with mutation burden, PDL1 expression patterns and clinical outcome. Method: Histologic sections of from 250 tumors were evaluated by two pathologists independently for squamous subtype (WHO classification), percentage and character of intratumoral inflammatory cells, percentage and character of para-tumoral infiltrate and presence or absence of scalloping at tumor cell/stromal interface by inflammatory cells along the edges of tumor cell nests, a feature possibly related to existing immune reaction. The ratios of infiltrating inflammatory cells to tumor cells were estimated in 10% increments by microscopic inspection. Quantity and character of infiltrates was assessed by Kaplan-Meir testing for effect on survival and by Pearson bivariate testing for relationships among variables. Result: The character and extent of inflammatory infiltrates were highly heterogeneous. The infiltrates could be divided into intratumoral and paratumoral patterns according to their location in relation to microscopic tumor cell nests. Intratumoral infiltrates could be further subdivided into two patterns: one consisted exclusively lymphocytes, usually few in number; a second polymorphous pattern contained many inflammatory cell types including polymorphonuclear leukocytes (PMNs). In paratumoral tissue, three patterns could be discerned: lymphocytic, plasmacytic and polymorphous. Inflammatory cell infiltrate quantity or character did not correlate with survival for either intratumoral or paratumoral infiltrates and there was no evident relationship to mutational burden or to PDL1 expression by IHC. Scalloping at the tumor cell stromal interface was also not prognostically significant. Conclusion: The inflammatory infiltrates in early stage squamous lung carcinoma are highly heterogenous and are not associated with outcome. However, the complexity of tumor infiltrating inflammatory cells is worthy of further evaluation in future immunotherapeutic trials. Background: Molecules targeting Programmed Death Receptor 1 (PD-1) and its ligand (PD-L1) are now part of the therapeutic arsenal for patients presenting with advanced stage non-small cell lung carcinoma (NSCLC). PD-L1 staining assessed by immunohistochemistry (IHC) is currently used as a predictive biomarker to select patients likely to respond to PD-1/PD-L1 inhibitors. Despite recent data, it is still not clear if cytology specimens provide reliable and valid PD-L1 results, when compared to tissue specimens. In this project, we aimed to compare PD-L1 IHC results on tissue (biopsy and surgery) and cytology specimens from the same patient. We also wanted to assess the performance of two IHC kits as well as the intra and interobserver agreement in evaluating cytology specimens. Method: A retrospective cohort comprising 46 patients with a diagnosis of NSCLC was selected. Each patient had a surgical specimen with a corresponding cytology sample (cell block), including 20 pleural effusions, and/or a biopsy, for a total of 182 specimens. IHC was performed using 28-8 and SP263 PD-L1 kits. PD-L1 staining was measured as the percentage of tumor cells with membranous staining (tumor proportion score, TPS) as rated blindly by four evaluators. Sixty slides were then blindly reevaluated for documenting intraobserver agreement. PD-L1 TPS was grouped as <1%, 1-49% and >50%. Fleiss and Cohen's kappas were used to evaluate TPS concordance between tissue and cytology specimens and to assess the inter and intraobserver agreement. Result: Respectively for 28-8 and SP263 kits, 37.5 and 25.0% of the 32 patients with a cytology sample had a PD-L1 TPS of >50% with a good agreement between the kits (k¼0.73, CI95% 0.50-0.97). The agreement between the cytology and surgical specimen was good (28-8: k¼0.76, CI95% 0.46-1.0, SP263: k¼0.75, CI95% 0.42-1.0) and was slightly lower between the 26 patients with a biopsy and a cytology specimen (28-8: k¼0 .71, CI95% 0.31-1.0, SP263: k¼0.67, CI95% 0.19-1.0). For the evaluation of PD-L1 TPS in cytology specimens, the interobserver agreement was good SP263: k¼0.63, ) and the intraobserver agreement was excellent (k¼0.93, CI95% 0.85-1.0). Conclusion: We showed that PD-L1 TPS evaluated in cytology samples have a good concordance with biopsy and surgical specimens. We also demonstrated that the evaluation in cytology specimen is feasible as the inter and intraobserver agreement was good to excellent. Overall, our results support the use of PD-L1 IHC on cytology specimens, however, this will need to be correlated with the clinical response to immunotherapy. Keywords: cytology, Immunotherapy, PD-L1 immunohistochemistry Background: Histological evaluation of surgical margin for pulmonary malignant tumor in sublobar resection is difficult in automatic suture instrument (stapler) used in thoracoscopic surgery. In order to solve this problem, we devised a novel surgical margin assessment method that combined with rapid-immunocytochemistry (R-ICC) of stapler lavage solution and examined its usefulness. We developed a device that enables rapid-IHC (R-IHC) analyses within 20 minutes. By applying this device to R-ICC, we can perform intraoperative R-ICC within 30 minutes. By using this method, it is a possibility that the surgical margin can be accurately evaluated more than papanicolaou staining alone. Method: From September 2016 to December 2017, we examined 21 lesions of pulmonary malignant tumor in 21 patients who underwent sublobar resection at Akita University Hospital. There were 12 male and 9 female patients whose ages ranged from 45 to 83 years old. Six patients underwent segmentectomy and 15 of ones underwent wedge resection. Histological diagnosis of staple stump and cytological diagnosis of staple lavage fluid (papanicolaou staining) and R-ICC were performed. The cases were classified by pathological results, and each cases were followed up. We performed R-ICC using each antibodies against for cytokelatin (CK) 20, CK 7 and Thyroid transcription factor-1 (TTF-1) in adenocarcinoma, p-40 in squamous cell carcinoma, respectively. Result: The histological diagnoses were 4 lung adenocarcinomas, 5 squamous cell carcinomas, 7 colorectal adenocarcinomas, 1 renal cell carcinoma, 1 hepatocellular carcinoma, 1 duodenal cancer, 1 endometrial cancer and 1 bile duct cancer. No histological diagnosis of staple stump observed malignant findings in all cases. On the other hand, in conventional cytological diagnoses there were 2 cases of class V, 1case of class IV and 1 case of class III. R-ICC were positive in all 4 cases of class III or higher. Among 4 cases, we performed additional resection in two cases of class V, but not in the other two cases because difficulty in further resection. In the case of class IV without additional resection, local recurrence was observed in 4 months after surgery. Conclusion: Among 21 cases, local recurrence was observed in one patient with positive cytological diagnosis and positive R-ICC diagnosis. There is a possibility that staple lavage fluid cytology can more accurately evaluate the stump than the tissue crushed by the staple. If there are very few cancer cells in the lavage fluid, R-ICC may be useful for cancer cell detection. Keywords: surgical margin, sublobar pulmonary resection, rapid-immunocytochemistry
